Company intelligence / Profile preview

Alentis Therapeutics

Allschwil/Basel, Basel-Country, Switzerlandalentis.ch ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Alentis has reported positive topline results for two fibrosis studies of lixudebart (ALE.F02), and received FDA Fast Track designation for ALE.P02. The company’s lead oncology asset ALE.C04 targets CLDN1 in solid tumors. Their pipeline includes first-in-class ADCs and mAbs targeting CLDN1 with clinical trials commencing or ongoing for both cancer and fibrosis indications[1][8].

Therapeutic areas: OtherOncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

5 assets

ALE.P02

4 more assets in the full pipeline.

Request access →

Partnerships

Supported by top-tier biotech investors including OrbiMed and Novo Holdings [9]

Beyond the preview

Go deeper on Alentis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alentis Therapeutics.

Explore the full profile